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Abstract
Background: Stem cell transplantation (SCT) is still complicated by the occurrence of fever and inflammatory complications
attributed to neutropenia and subsequent infectious complications. The role of mucosal barrier injury (MBI) of the intestinal
tract therein has received little attention.
Methods: We performed a retrospective analysis in 163 SCT recipients of which data had been collected prospectively on
intestinal damage (citrulline), inflammation (C-reactive protein), and neutrophil count. Six different conditioning regimens
were studied; 5 myeloablative (MA) and 1 non-myeloablative (NMA). Linear mixed model multivariate and AUC analyses
were used to define the role of intestinal damage in post-SCT inflammation. We also studied the relationship between the
degree of intestinal damage and the occurrence of early post-SCT complications.
Results: In the 5 MA regimen there was a striking pattern of inflammatory response that coincided with the occurrence of
severe intestinal damage. This contrasted with a modest inflammatory response seen in the NMA regimen in which
intestinal damage was limited. With linear mixed model analysis the degree of intestinal damage was shown the most
important determinant of the inflammatory response, and both neutropenia and bacteremia had only a minor impact. AUC
analysis revealed a strong correlation between citrulline and CRP (Pearson correlation r=0.96). Intestinal damage was
associated with the occurrence of bacteremia and acute lung injury, and influenced the kinetics of acute graft-versus-host
disease.
Conclusion: The degree of intestinal damage after myeloablative conditioning appeared to be the most important
determined the inflammatory response following SCT, and was associated with inflammatory complications. Studies should
explore ways to ameliorate cytotoxic therapy-induced intestinal damage in order to reduce complications associated with
myeloablative conditioning therapy.
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Introduction
Treating patients with hematological malignancies by use of a
hematopoietic stem cell transplantation (SCT) is still complicated
by the occurrence of infections and inflammatory complications
including sepsis, acute lung injury, and graft-versus-host disease
(GvHD). Historically the focus was on neutropenia and fever
(‘‘febrile neutropenia’’) and its relation to infections [1]. However,
a substantial number of SCT recipients develop fever unrelated to
infection (‘‘unexplained fever’’) [2], resulting from other causes
including cytotoxic therapy-induced mucosal barrier injury (MBI)
[3,4].
Many studies have shown associations between the magnitude
of the C-reactive protein (CRP) response and cytokine release and
post-SCT complications [5–9], and these complications might
therefore best be regarded as manifestations of a systemic
inflammatory response syndrome (SIRS) [8]. Other studies have
shown that infections may contribute to non-infectious complica-
tions including acute GvHD [10,11]. However, few if any of these
studies addressed the role of MBI per se as an isolated cause of
inflammation and risk factor for infections, nor its role in the
pathogenesis of inflammatory complications. Animal models have
enhanced our understanding of the inflammatory processes that
take place in the intestine following chemotherapy [12–14], and in
the clinical setting of SCT the relationship between intestinal
damage and the inflammatory response has become better
appreciated [4,15]. Mucosal damage and deregulated host-
microbial interactions have also been shown to contribute to
SIRS and post-SCT complications such as acute GvHD [16,17].
Therefore, we hypothesized that intestinal damage could be the
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with chemotherapy and radiotherapy and that the degree of
damage correlates with the occurrence of post-SCT complications.
Studying damage to the gastro-intestinal tract during SCT
remains difficult, since it remains hidden and hitherto only indirect
and non-specific tests were available [18,19]. Measuring serum or
plasma citrulline levels provides a more direct and specific way of
determining intestinal damage of certain conditions that are
accompanied by gut failure [20]. Recently, citrulline-based
assessment of intestinal damage has also shown to be objective,
reproducible, specific and reliable in the setting of SCT [21,22].
To test our hypothesis we studied the relationship between the
magnitude of the inflammatory response and the degree of
intestinal damage as measured by citrulline, the duration of
neutropenia, and the occurrence of bacteremia. To achieve this we
selected recipients of a SCT for which 5 cohorts of patients had
been given different myeloablative (MA) conditioning regimens
and a single cohort had received a non-myeloablative (NMA)
conditioning regimen. We also investigated whether we could
determine a relationship between the degree of intestinal damage
and the occurrence of early post-SCT complications.
Materials and Methods
Study population
This was a retrospective analysis of 163 patients who had
received an autologous or allogeneic SCT in our hospital from
May 2004 to December 2007. Plasma had been collected
prospectively and stored for later analysis of citrulline, but other
data including CRP, temperature, and clinical and microbiological
infections had been prospectively gathered from the day of starting
chemotherapy. Patients had given their informed consent to the
prospective collection of data and plasma samples for investiga-
tional use. The local ethics committee (CMO Regio Arnhem-
Nijmegen) judged that no formal approval for this study was
necessary regarding the fact that data were used anonymously and
the analysis would not reveal results harming contributing patients.
Conditioning regimens and stem cell transplantation
The MA and NMA regimens are depicted in Table 1. All
patients received a stem cell graft on the day scheduled.
Autologous SCT grafts contained at least 2.0610
6 CD34+ cells
per kg, and allogeneic SCT partially T cell-depleted grafts
contained on average 3.0610
6 CD34+ cells per kg and 0.5610
6
CD3+ cells per kg.
Treatment protocol
All patients were treated according to the same protocol, which
has been described earlier [23]. GvHD prophylaxis consisted of
cyclosporine only. Anti-microbial prophylaxis consisted of cipro-
floxacin and valacyclovir. Fever was defined by a single axillary
temperature $38.5uC. At the onset of fever 40 mL of peripheral
blood was obtained for culture together with 10 mL from each
lumen of the catheter, patients were examined for any sign of local
infection, and empirical therapy with ceftazidime was started [24].
Neutropenia was defined as an ANC#0.5610
9/L, and the
duration and depth was recorded. CRP levels (mg/L) were
determined every day and the maximum CRP (CRPmax) recorded.
Plasma citrulline was determined to estimate intestinal damage
before the start of conditioning and 3 times weekly thereafter until
discharge. Citrulline concentrations (mmol/L) were measured by a
standard procedure for determining amino acids using high-
performance liquid chromatography [21]. Citrulline levels below
10 mmol/L were deemed to indicate hypocitrullinemia, and were
regarded as reflecting severe intestinal damage [20].
Definition of stem cell transplantation complications
Clinical and microbiologically defined infections were defined
according to the Consensus definitions of Immunocompromised
Host Society [2]. A blood culture was considered to represent
bacteremia if one or more bottles yielded a microorganism, except
in the case of coagulase-negative staphylococci (CoNS), which
required recovery of the same strain from two separate positive
blood cultures [24]. The incidence of bacteremia that occurred on
Table 1. Conditioning regimens.
Regimen Doses Frequency Days Type of conditioning Type of SCT, day
HDM
-Melphalan 100 mg/m
2 Od 1, 2
MA Autologous, day 4
BEAM
-Carmustine (BCNU)
-Etoposide.
-Cytarabine
-Melphalan
300 mg/m
2
100 mg/m
2
100 mg/m
2
140 mg/m
2
Od
Bd
Bd
Od
1
2-5
2-5
6
MA Autologous, day 7
Ida-Cyclo-TBI:
-Idarubicine
-Cyclophosphamide
-TBI
42 mg/m
2
60 mg/kg
4.5 Gy
Infusion over 48 h
Od
Od
1
7, 8
11, 12
MA Allogeneic
Matched related donor, day
13
Cyclo-ATG-TBI
-Cyclophosphamide
-Thymoglobuline
-TBI
60 mg/kg
2 mg/kg
4.5 Gy
Od
Od
Od
1, 2
3-6
7, 8
MA Allogeneic
Matched unrelated donor,
day 9
Cyclo-TBI:
-Cyclophosphamide
-TBI
60 mg/kg
4.5 Gy
Od
Od
1, 2
5, 6
MA Allogeneic
Matched related donor, day
7
Cyclo-Flu:
-Cyclophosphamide
-Fludarabine
1200 mg/m
2
30 mg/m
2
Od
Od
1-4
1-4
NMA Allogeneic
Matched related donor, day
7
Abbreviations: od; once daily, bd; two times daily, TBI=total body irradiotion, MA=myeloablative, NMA=non-myeloablative.
doi:10.1371/journal.pone.0015156.t001
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regimens. Invasive fungal diseases were scored according to the
EORTC/MSG consensus guidelines [25]. Acute lung injury (ALI)
was defined according to current guidelines [26]. Acute GvHD,
GvHD occurring the first 100 days after SCT, was graded
according to the criteria of Przepiorka et al. [27]. Early mortality
related to SCT complications was defined as any death occurring
within 30 days following SCT (day +30), but unrelated to the
underlying disease.
Data analysis
We employed descriptive statistics for fever, neutrophil count,
CRP levels, and citrulline levels which were expressed as mean
values together with the 95% confidence interval (Table 2). As
citrulline was measured three times weekly, the real nadir might
have been attained between two measurements and hence was
likely missed. To compensate for this and study the true length of
time in which citrulline levels were below 10 mmol/L we modeled
the course of citrulline as a function of time during the first 30 days
by developing a linear mixed model using first, second, third and
fourth power of time as fixed factors to predict the citrulline levels
after taking into account the within-person correlations by
incorporating a random patient intercept. To describe the
relationship of CRP to the neutrophil count, intestinal damage
(citrulline concentration) and bacteremia we used several linear
mixed models for the first 30 days with random patient effect and
the logarithmic transformed CRP (log CRP) as the outcome
variable.
To assess the impact of conditioning on intestinal damage and
CRP we performed an area under the curve (AUC) analyses. Per
patient, the CRPAUC was defined as the sum of the 30 estimated
CRP values, resulting from a piecewise linear mixed model which
uses a linear time component for day 1–10 and a cubic time
component for day 11–30. The conditioning regimen and the
interactions between the particular regimen and time were also
part of this model that also accounted for within person
correlations by virtue of a random intercept. Likewise, the
citrullineAUC per patient was defined as the sum of the 30
estimated 10/citrulline values. We used the citrulline levels
estimated by the linear mixed model described above and
transformed these values into 10 times the inverse of the estimated
value.
Comparisons between the impact of the different conditioning
regimens on neutropenia, CRPAUC and citrullineAUC were studied
Table 2. General characteristics.
Conditioning
HDM
(N=56)
BEAM
(N=21)
Ida-Cyclo-TBI
(N=28)
Cyclo-ATG-TBI
(N=34)
Cyclo-TBI
(N=10)
Cyclo-Flu
(N=14)
Age, mean (range), years 56 (33-65) 47 (18-65) 46 (18-64) 43 (20-58) 50 (38-59) 54 (39-65)
Gender: M/F 35/21 17/4 13/15 21/13 8/2 10/4
Diagnoses:
-MM
-NHL/CLL
-AML
-ALL
-MDS
-CML/MPD
56 (100%)
-
-
-
-
-
-
21 (100%)
-
-
-
-
-
7 (25%)
12 (42.5%)
3 (10.5%)
6 (22%)
-
-
13 (38%)
8 (23.5%)
4 (11.75%)
4 (11.75%)
5 (15%)
8 (80%)
2 (20%)
-
-
-
14 (100%)
-
-
-
-
-
Type of conditioning MA MA MA MA MA NMA
Type of SCT Autologous Autologous Matched sibling
allogeneic
Matched unrelated
allogeneic
Matched sibling
allogeneic
Matched sibling
allogeneic
Fever (axillary temperature $ 38.5
0C) 88.0% 90.5% 100% Early: 73.5%
Late: 100%
100% Early: 28.6%
Late: 78.6%
Fever, day from start conditioning, mean
(95%CI)
11.8 (11.4-12.2) 13.0 (12.2-13.9) 12.9 (12.2-13.6) 4.1 (3.7-4.5)
14.1 (13.0-15.1)
13.4 (12.0-14.8) 3.0 (1.7-4.3)
16.0 (14.4-17.5)
Neutrophils ,0.5 x10
9/L, days (95%CI) 8.4 (8.0-8.7) 9.5 (8.5-10.5) 15.8 (14.6-17.0) 15.5 (14.6-16.4) 11.1 (9.8-12.4) 12.4 (10.8-14.1)
Citrulline ,10 mmol/L, number of
patients, (%)
51 (91%) 21 (100%) 26 (93%) 30 (88%) 10 (100%) 4 (29%)
Measurements with citrulline ,10 mmol/L,
mean (95%CI)*#
3.5 (3.2-3.9) 4.7 (4.0-5.3) 6.2 (4.6-7.8) 4.8 (4.0-5.7) 3.5 (2.4-4.6) 3.0 (1.1-4.9)
Observed citrulline nadir mmol/L, mean
(95%CI)*
6.0 (5.4-6.6) 4.3(3.5-5.1) 4.6 (3.9-5.3) 5.6 (4.9-6.3) 5.6 (4.2-7.0) 10.8 (8.9-12.6)
Citrulline ,10 mmol/L, days, mean
(95%CI)&#
7.9 (7.1-8.7) 11.2 (9.6-12.9) 17.7 (15.6-19.8) 14.6 (13.3-15.9) 11.0 (7.9-14.1) 7.5 (5.4-9.6)
Citrulline nadir mmol/L, mean (95%CI)& 6.5 (5.7-7.2) 4.9 (3.7-6.0) 4.5 (3.5-5.7) 7.0 (6.1-7.9) 6.6 (5.1-8.1) 12.4 (10.2-14.6)
CRPmax (mg/L), mean (95%CI) 163 (136-189) 202(160-246) 257 (222-291) 188 (162-213) 211 (154-269) 66 (38-95)
Characteristics of patients, stem cell transplantation and general outcome measures of intestinal damage (citrulline), inflammation (CRP and fever), and neutropenia
(neutrophil count #0.5610
9/L) for each conditioning regimen.
*Citrulline was measured 3 times weekly.
#Only those patients included with citrulline levels below 10 mmol/L.
&Based on estimated values. MA=myeloablative, NMA=non-myeloablative, CRP=C-reactive protein, MM=multiple myeloma, NHL=non-Hodgkin lymphoma,
CLL=chronic lymphatic leukemia, AML/ALL=acute myeloid and lymphatic leukemia, MDS=myelodysplastic syndrome, CML/MPD=chronic myeloid leukemia/
myeloproliferative disease.
doi:10.1371/journal.pone.0015156.t002
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of neutropenia and CRPAUC versus citrullineAUC and CRPAUC
was studied by Pearson correlation over the different regimens.
Comparison of the mean onset of acute GvHD between the
different regimens was done using one-way ANOVA. Comparison
of the incidence of ALI in relation to OVS between the different
regimens was done using the x
2-test.
Analyses were performed using SAS 8.2 and a P-value of ,0.05
was considered to indicate statistical significance.
Results
Study population and patient characteristics
Seventy-seven (77) patients received an autologous and 86 an
allogeneic SCT (Table 2). All but 14 patients received MA
conditioning. Autologous SCT was performed for patients with
multiple myeloma and non-Hodgkin lymphoma, but allogeneic
SCT was employed for a greater variety of diagnoses including
acute and chronic lymphatic and myeloid leukemia and
myelodysplastic syndrome. NMA conditioning was employed to
prepare patients who had received an autologous SCT 4–6
months earlier for MM.
Intestinal damage
MA conditioning was associated with severe and prolonged
intestinal damage shown by a rapid decline in citrulline to
,10 mmol/L, a mean of 10 days after starting chemotherapy. The
mean nadir of citrulline was 4.5–7.0 mmol/L, and hypocitrulline-
mia lasted for more than one week in most patients (Figure 1A–E,
Figure 2A, Table 2). Hypocitrullinemia was most pronounced in
patients receiving idarubicin in their conditioning, lasting
approximately 18 days. In contrast, an early and short drop of
citrulline level was noticed for NMA conditioning, but hypoci-
trullinemia was not evident for most patients (Figure 1F, Figure 2A,
Table 2).
Inflammatory response measured by C-reactive protein
and fever
The course of CRP during SCT of the different conditioning
regimens is illustrated in Figure 1 and Figure 2B. Within each type
of MA conditioning, patients showed similar patterns of
inflammatory response, although there was some variation in the
precise onset, peak and resolution of CRP levels. Those without
bacteremia did not have a different course when compared to
those with; although in general CRP levels were lower (data not
shown). As for intestinal damage, the CRP response was highest in
patients receiving idarubicin. Resolution of inflammation occurred
with engraftment and restoration of the intestinal damage defined
by rising citrulline levels. In Cyclo-ATG-TBI conditioning the first
peak of CRP was related to ATG induced lymphocyte depletion
and cytokine release, but the second peak resembled that seen for
the other MA regimens. Also some patients treated with Cyclo-
TBI and BEAM had an early peak in CRP during conditioning,
which was probably related to chemotherapy induced cytokine
release.
Only a moderate inflammatory response occurred after NMA
(Figure 1F and Figure 2B). Also, the timing was different when
compared to MA regimens with a peak occurring early during
conditioning and a second peak much later. The latter occurred
during engraftment and thereby resembled to some extent the
inflammatory complication designated engraftment syndrome
[28].
Virtually every patient who had received MA developed fever as
did 80% of those given NMA conditioning. Some patients
receiving Cyclo-ATG-TBI and Cyclo-Flu also experienced an
early episode with fever during conditioning (25 and 4 patients,
respectively). In MA regimens fever occurred on days 12–14, 2–3
days after CRP had become elevated (Figure 1, Table 2). By
contrast, fever occurred late during engraftment at a mean of day
16 after starting NMA conditioning.
Relation intestinal damage to inflammation
In MA conditioning CRP levels started to increase from 10–11
following the start of conditioning which coincided with the
development of hypocitrullinemia (Figure 1A–E and Figure 2).
The peak of the inflammatory response coincided with the nadir of
citrulline levels. Although interindividual differences existed the
occurrence of inflammation was related to the development of
intestinal damage in almost every patient.
Additional AUC analysis was used to grade the impact of
conditioning on intestinal damage and CRP. There were
significant differences in both CRPAUC and citrullineAUC between
the various conditioning regimens (Kruskal-Wallis P,0.001),
except between BEAM, Cyclo-TBI, and Cyclo-ATG-TBI. Inter-
estingly, a very strong correlation between the degree of intestinal
damage and the inflammatory response was seen for the different
regimens (Pearson correlation 0.96, Figure 3). By contrast, there
was only a weak correlation between the duration of neutropenia
and inflammation (Pearson correlation 0.48, Figure 3).
In univariate linear mixed model analysis, 10/citrulline, the
type of conditioning regimen, neutropenia and bacteremia were
significantly associated with log CRP. In multivariable analyses
only citrulline and type of conditioning regimen remained
important.
Stem cell transplantation complications
Bacteremia. There was a significant difference between MA
and NMA regarding bacteremia on the day of fever (Table 3) with
up to 85% of patients experiencing bacteremia predominantly due
to oral viridans streptococci (OVS) and CoNS after MA
conditioning, compared with none of those receiving NMA
(P,0.001). OVS was recovered with CoNS in 20/55 (36%) of
cases. A minority of patients experiencing a bacteremia with
CoNS on the day of fever had any clinical or radiological signs of a
CVC related tunnel infection or thrombophlebitis at the same time
(5/55 (9%)).
Acute lung injury. The overall incidence of ALI was 18/163
(11%), with 14/18 (78%), being associated with OVS bacteremia.
Conversely, ALI affected 14/53 (26.4%) patients with OVS
bacteremia. However, this incidence varied significantly between
conditioning regimens and was related to the severity of intestinal
damage as ALI occurred in 3/22 (13.6%), 4/13 (30.8%) and 4/7
(57.1%) in patients receiving HDM, Cyclo-ATG-TBI, and Ida-
Cyclo-TBI conditioning, respectively (P=0.03) (Table 3).
Acute graft-versus-host disease. No differences were seen
in the total incidence of acute GvHD, although there were no
cases of acute GvHD III-IV in the group with NMA; with only
skin acute GvHD being encountered. However, there was a
significant difference in the onset of acute GvHD. In Ida-Cyclo-
TBI and Cyclo-TBI, despite receiving a partially T-cell-depleted
graft, acute GvHD occurred early with a mean onset on day +25
post SCT. In both Cyclo-ATG-TBI and Cyclo-Flu the onset was
delayed, with a mean onset on day +46 and +40 post SCT,
respectively (P=0.02).
Early mortality. Overall, early mortality was low 6/163
(3.7%), and related to ALI and acute GvHD, and all but one death
occurred following MA conditioning for an allogeneic SCT.
Intestinal Damage in SCT
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In this study we show the course and extent of intestinal damage
and inflammatory responses following various conditioning
regimens used to prepare for a hematopoietic SCT. There was a
striking pattern of inflammatory response coinciding with the
occurrence of severe intestinal damage for patients receiving MA
conditioning, defined by hypocitrullinemia [20]. Moreover, the
degree of intestinal damage seemed the most important determi-
nant of inflammation and was highly correlated with the
magnitude of the inflammatory response measured by CRP.
Neither neutropenia nor bacteremia had a major impact on this.
The close relationship between intestinal damage and inflamma-
tion was further underscored by the fact that NMA resulted in only
a modest inflammatory response with a completely different time
Figure 1. Course of citrulline and CRP in time after start of conditioning. Five MA and one NMA conditioning regimens are shown; A=HDM,
B=BEAM, C=Ida-Cyclo-TBI, D=Cyclo-ATG-TBI, E=Cyclo-TBI, F=Cyclo-Flu. Observed values (N), mean values (#).
doi:10.1371/journal.pone.0015156.g001
Figure 2. Summary of the time course of citrulline (A) and CRP
(B) for all 6 regimens. Day 1 is the day of start of conditioning. To
correct for unobserved citrulline and CRP values we modeled the course
of citrulline and CRP as described in methods. 1=HDM, 2=BEAM,
3=Ida-Cyclo-TBI, 4=Cyclo-ATG-TBI, 5=Cyclo-TBI, 6=Cyclo-Flu. Mean
CRP in mg/L, mean citrullline in mmol/L.
doi:10.1371/journal.pone.0015156.g002
Figure 3. Pearson correlation between the mean degrees of
neutropenia (NP in days) and inflammation (CRPAUC) versus
intestinal damage (CitrullineAUC) and inflammation (CRPAUC)
over the different regimens. 1=HDM, 2=BEAM, 3=Ida-Cyclo-TBI,
4=Cyclo-ATG-TBI, 5=Cyclo-TBI, 6=Cyclo-Flu.
doi:10.1371/journal.pone.0015156.g003
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Consequently, intestinal damage appears the primary determinant
of inflammation following myeloablative conditioning with chemo-
and radiotherapy in the setting of autologous and allogeneic SCT.
While there are limitations associated with retrospective analysis
and the potential for bias resulting from selection, the relationship
of intestinal damage to SCT complications was remarkable. As
expected, there was a significant difference in occurrence of
bacteremia between those receiving MA and NMA conditioning
[29]. The similar duration of neutropenia and the marked
difference in intestinal damage, suggest that the gut may have
been the origin of bacteremia [30]. Moreover, most pathogens
recovered from blood cultures are known residents of the gut
[31,32]. Notably, a considerable proportion of patients had
bacteremia with both CoNS and OVS, which was probably due
to simultaneous intestinal translocation [31].
A strong relationship has been found between the occurrence of
OVS bacteremia and septic shock and ALI in neutropenic
patients, which was explained by virulence factors and pulmonary
cytotoxicity of chemotherapy [33–35]. Interestingly, we saw that in
patients with OVS bacteremia the incidence of ALI was related to
the degree of intestinal damage. It is known that barrier
dysfunction facilitates bacterial translocation, but intestinal
damage also seems to determine the resulting inflammatory
response. This was confirmed in our linear mixed model, which
showed citrulline but not bacteremia related to the CRP response.
Although ALI seems directly associated with OVS bacteremia this
might be only coincidental, as both complications are conse-
quences of severe intestinal damage. So intestinal damage ‘primes’
the immune system with subsequent aggravated cytokine release
following activation of pattern recognition receptors from
translocating microbial motifs [13].
This ‘priming’ of the immune system also applies to the
occurrence acute GvHD in which the role of intestinal damage has
been acknowledged [16]. Although we found no apparent
differences in the citrulline and CRP levels between patients with
and without acute GvHD within any given regimen, between
regimens there was a clear difference in the kinetics of acute
GvHD. In addition severe acute GvHD did not develop after
NMA, as opposed to 6–10% after MA, and GvHD of liver or gut
did not occur. The early onset of acute GvHD after Ida-Cyclo-
TBI and Cyclo-TBI suggests that the tissue inflammation resulting
from the profound intestinal damage, contributes to the acceler-
ated allo-reactive T-cell response [36], even in the setting of partial
T cell-depletion. The delay in onset of acute GvHD in patients
conditioned with ATG results from additional in vivo T cell-
depletion creating a ‘time-window’ between the intestinal damage
induced inflammation and T cell recovery. After NMA we also
saw a delay in the onset of acute GvHD, which is in accordance
with previous data from studies in mice [37] and humans [38].
This altered kinetics of acute GvHD was, at least in part, related to
the absence of significant intestinal damage and tissue inflamma-
tion. Differences in the kinetics of acute GvHD in NMA have been
largely attributed to alterations in antigen presenting cell
chimerism, T cell chimerism and regulatory T cell activation
[37], but our data underscore the role conditioning-induced
intestinal damage plays in the complex pathogenesis of acute
GvHD.
Several studies have shown correlations between CRP and the
occurrence of SCT complications but they all used different cut-off
values [5,7]. CRP is not a specific marker since chemotherapy and
ATG and, the process of engraftment itself, elicit inflammatory
responses. Hence it is not possible to identify who is at risk or when
that risk might occur. Citrulline could provide an alternative,
because it is a specific marker of enterocyte mass, which decreases
only when there is intestinal damage. Furthermore, citrulline levels
correspond with the inflammatory responses following MA
conditioning, and more importantly with SCT complications.
Table 3. Stem cell transplantation complications.
SCT complications
HDM
(N=56)
BEAM
(N=21)
Ida-Cyclo-TBI
(N=28)
Cyclo-ATG-TBI
(N=34)
Cyclo-TBI
(N=10)
Cyclo-Flu
(N=14)
Bacteremia on day of fever
-OVS
-CoNS
-Other
29
22 (39.3%)
12 (21.4%)
2
10
6 (28.5%)
7 (33.3%)
-
18
7 (25%)
12 (46.5%)
1
29
13 (38%)
21 (65%)
1
6
5 (50%)
3 (20%)
-
0
-
-
-
Concomitant OVS/CoNS 7 3 2 6 2 NA
Candidemia 1 0 3 1 0 0
Clinically defined infection:
-Phlebitis superficial vein.
-Tunnel infection/infected thrombosis
-Pneumonia.
-Probable/Proven IA.
5
-
1
4
-
5
-
3
2
-
9
-
5
2
1
7
-
6
-
1
3
-
1
1
1
3
1
-
2
-
ALI
ALI following OVS bacteremia
4/56 (7.1%)
3/22 (13.6%)
2/21 (9.5%)
1/6 (16.7%)
6/28 (21.5%)
4/7 (57.1%)
4/34 (11.8%)
4/13 (30.8%)
2/10 (20%)
2/5 (40%)
0
Early mortality (day +30 post SCT)
-ALI.
-Acute GvHD
0
-
-
1
1
-
2
1
1
1
-
1
2
1
1
0
-
-
aGvHD I-IV, all (N, %)
-Grade II-IV
-Grade III-IV
NA NA 13/28 (46%)
8 (28.5%)
2 (7%)
12/34 (28%)
7 (20.5%)
2 (6%)
6/10 (60%)
3 (30%)
1 (10%)
6/14 (43%)
4 (28.5%)
-
Onset from day SCT, mean (95%CI) NA NA 26 (16-36) 46 (29-63) 23 (19-27) 40 (19-61)
OVS=oral viridians streptococci, CoNS=coagulase-negative staphylococci, IA=invasive Aspergillosis, ALI=acute lung injury, acute GvHD=acute graft-versus-host
disease. Grading of acute GvHD was done according to the criteria of Przepiorka et al. [27] and probable/proven IA was defined according to EORTC/MSG consensus
definitions [25].
doi:10.1371/journal.pone.0015156.t003
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15156Clearly it is necessary to confirm the predictive value of citrulline
for individual patients and to define cut-off values more precisely.
Classifying other conditioning regimens, by means of measuring
citrulline can already help determine the need for antimicrobial
prophylaxis, hospital care, and the use of anti-inflammatory
treatment.
Given the role of intestinal MBI in complications after SCT
studies should explore ways to ameliorate cytotoxic therapy-
induced intestinal damage in order to reduce inflammatory
complications associated with myeloablative conditioning therapy.
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